EUROIMMUN POLSKA Sp. z o.o., Widna Str. 2a, 50-543 Wroclaw, Poland.
Department of Laboratory Diagnostics, Diagnostics Laboratory for Teaching and Research, Wroclaw Medical University, Borowska Str. 211a, 50-556 Wroclaw, Poland.
Medicina (Kaunas). 2020 May 20;56(5):244. doi: 10.3390/medicina56050244.
Tick-borne encephalitis virus (TBEV) infections have been the cause of threatening outbreaks for many years. Apart from several physical and chemical methods to prevent tick bites, active vaccination of people highly exposed to infection is still the most important strategy of prevention. However, in some subjects, the lack of or low response to TBEV antigens is observed. The aim of the current study was to assess the prevalence of seronegative rate for anti-TBEV antibodies and the risk factors for waning immunity. 2315 at least primary vaccinated subjects from the high risk group for TBEV infections participated in this study. A commercial enzyme-linked immunosorbent assay (ELISA) test was used for the assessment of anti-TBEV IgG serum level. Data showed that 86.2% of subjects who underwent vaccination were positive for anti-TBEV antibodies within 5 years. As much as 13.8% of subjects that underwent primary or primary and booster vaccination were barely protected after vaccination. Women and subjects under 60 years underwent more effective protection but sex and older age was not a risk factor for being a subject of waning immunity. A logistic regression showed that both a longer time since the vaccination and a lower number of booster doses constantly increased the chance of lost anti-TBEV antibodies. This study demonstrates that the vaccination schedule should be reevaluated. The extension of the interval of booster immunization is risky and all subjects should be surrounded by care consisting of more frequent monitoring of serum antibodies by personalized schedule to adjust the frequency of subsequent doses of booster vaccination.
蜱传脑炎病毒(TBEV)感染多年来一直是威胁性爆发的原因。除了几种预防蜱叮咬的物理和化学方法外,对高度感染风险的人群进行主动疫苗接种仍然是预防的最重要策略。然而,在某些情况下,会观察到对 TBEV 抗原缺乏或低反应。本研究旨在评估抗 TBEV 抗体的血清阴性率的流行率和免疫减弱的危险因素。 本研究共纳入了 2315 名至少接受过一次 TBEV 感染高风险人群的初级疫苗接种者。采用商业酶联免疫吸附试验(ELISA)检测抗 TBEV IgG 血清水平。 数据显示,在接种疫苗的 5 年内,86.2%的受试者对 TBEV 抗体呈阳性。多达 13.8%的接受过初级或初级和加强免疫的受试者在接种后几乎没有得到保护。女性和 60 岁以下的受试者得到了更有效的保护,但性别和年龄较大并不是免疫减弱的危险因素。逻辑回归显示,接种疫苗后时间的延长和加强剂量的减少都会增加失去抗 TBEV 抗体的机会。 本研究表明,应重新评估疫苗接种计划。延长加强免疫间隔时间是有风险的,所有受试者都应得到精心护理,包括通过个性化计划更频繁地监测血清抗体,以调整随后加强免疫接种剂量的频率。